Article
Oncology
Jad Zreik, Panagiotis Kerezoudis, Mohammed Ali Alvi, Yagiz U. Yolcu, Sani H. Kizilbash
Summary: Despite the inclusion of 1p/19q codeletion as a required diagnostic component for oligodendrogliomas in the 2016 WHO classification, study findings revealed persistent regional disparities in reported testing and identified new disparities in race/ethnicity that may impact patient management. Patients who underwent reported testing were more likely to receive adjuvant treatment, highlighting the importance of comprehensive testing for better treatment outcomes.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Luisa Allwohn, Josy Wolfgang, Julia Onken, David Wasilewski, Siyer Roohani, Daniel Zips, Felix Ehret, David Kaul
Summary: This study analyzes the influence of various tumor and patient characteristics on survival outcomes in patients with oligodendrogliomas (ODG) who have the 1p/19q-codeletion and IDH mutation. The results show that extent of resection, radiotherapy, and chemotherapy are associated with improved progression-free survival (PFS) in WHO grade 2 ODG, while only radiochemotherapy contributes to decreased risk of progression in WHO grade 3 ODG.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Article
Oncology
Kurt A. Jaeckle, Karla Ballman, Martin van den Bent, Caterina Giannini, Evanthia Galanis, Paul D. Brown, Robert B. Jenkins, J. Gregory Cairncross, Wolfgang Wick, Michael Weller, Kenneth D. Aldape, Jesse G. Dixon, S. Keith Anderson, Jane H. Cerhan, Jeffrey S. Wefel, Martin Klein, Stuart A. Grossman, David Schiff, Jeffrey J. Raizer, Frederick Dhermain, Donald G. Nordstrom, Patrick J. Flynn, Michael A. Vogelbaum
Summary: The study demonstrated that patients treated with temozolomide alone had significantly shorter progression-free survival (PFS) compared to those receiving radiotherapy. Patients not receiving radiotherapy also had shorter PFS, but there was no significant difference in overall survival. There were no significant differences between groups in terms of adverse events and neurocognitive decline.
Article
Pathology
Dario de Biase, Giorgia Acquaviva, Michela Visani, Gianluca Marucci, Antonio De Leo, Thais Maloberti, Viviana Sanza, Enrico Di Oto, Enrico Franceschi, Antonella Mura, Moira Ragazzi, Silvia Serra, Elisabetta Froio, Alessandra Bisagni, Alba A. Brandes, Annalisa Pession, Giovanni Tallini
Summary: The study developed a next-generation sequencing panel to simultaneously define 1p/19g codeletion and IDH1/IDH2 mutation status, providing a reliable and cost-effective alternative for molecular diagnostics in gliomas.
JOURNAL OF MOLECULAR DIAGNOSTICS
(2021)
Article
Clinical Neurology
Ahmet Kursat Karaman, Bora Korkmazer, Nil Urganci, Guelcin Bas, Serdar Arslan, Nil Comunoglu, Mehmet Murat Hanci, Osman Kizilkilic
Summary: This case report describes a rare case of oligodendroglioma with spinal drop metastases, which is the first molecularly-defined spinal metastatic oligodendroglioma. Oligodendroglioma patients with spinal cord-related symptoms should be aware of the possibility of drop metastases. Currently, there is no standard approach for the diagnosis and treatment of spinal metastases of this type of glial tumor.
FRONTIERS IN NEUROLOGY
(2022)
Article
Oncology
Mythili Merchant, Margarita Raygada, Ying Pang, Martha Quezado, Mark Raffeld, Liqiang Xi, Jung Kim, Manoj Tyagi, Zied Abdullaev, Olga Kim, Zach Sergi, Tina Pillai, Byram Ozer, Kareem Zaghloul, John D. Heiss, Terri S. Armstrong, Mark R. Gilbert, Kenneth Aldape, Jing Wu
Summary: Most tumors, including brain tumors, occur sporadically. However, there is a small subset of central nervous system tumors that are associated with Lynch Syndrome. This report presents a rare case of an oligodendroglioma with a PMS2 mutation associated with Lynch Syndrome. The limited literature on germline PMS2 mutations and oligodendrogliomas highlights the importance of genetic testing in neuro-oncology.
FRONTIERS IN ONCOLOGY
(2022)
Article
Clinical Neurology
Qinghui Zhu, Shaoping Shen, Chuanwei Yang, Mingxiao Li, Xiaokang Zhang, Haoyi Li, Xuzhe Zhao, Ming Li, Yong Cui, Xiaohui Ren, Song Lin
Summary: A prognostic model for oligodendroglioma patients was established using CGGA data, and the predictive accuracy of the model was validated in a separate cohort, demonstrating its potential in guiding personalized treatment.
FRONTIERS IN NEUROLOGY
(2022)
Article
Neurosciences
Derek Wong, Tae Hoon Lee, Amy Lum, Valerie Lan Tao, Stephen Yip
Summary: In this study, the transcriptomic and proteomic profiles of low-grade gliomas (LGG) were investigated using RNA-seq data and tandem mass-spectrometry analysis. The results showed that gene expression in LGG subtypes was mainly influenced by IDH mutations and 1p19q co-deletion. Proteomic analysis identified subtype-specific proteins that could be used to classify the LGG subtypes.
ACTA NEUROPATHOLOGICA COMMUNICATIONS
(2022)
Article
Pathology
Sakun Santisukwongchote, Chinnachote Teerapakpinyo, Piyamai Chankate, Piti Techavichit, Atthaporn Boongird, Sith Sathornsumetee, Samasuk Thammachantha, Pornsuk Cheunsuchon, Jantima Tanboon, Paul Scott Thorner, Shanop Shuangshoti
Summary: This study successfully achieved integrated diagnosis of diffuse gliomas in adult Thai patients using a simplified approach combining clinical, morphological, immunohistochemical, and fewer molecular tests, saving 50% of testing costs. The demographic data and tumor subtypes were similar to series from other regions of the world.
PATHOLOGY RESEARCH AND PRACTICE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Laura Mancini, Stefano Casagranda, Guillaume Gautier, Philippe Peter, Bruno Lopez, Lewis Thorne, Andrew McEvoy, Anna Miserocchi, George Samandouras, Neil Kitchen, Sebastian Brandner, Enrico De Vita, Francisco Torrealdea, Marilena Rega, Benjamin Schmitt, Patrick Liebig, Eser Sanverdi, Xavier Golay, Sotirios Bisdas
Summary: This study investigated the clinical value of different CEST metrics for glioma classification and found that CEST-derived biomarkers for amides, amines, and their ratio are useful for histomolecular staging in gliomas. The study also revealed that AB/FS CEST mismatch can identify glioma subgroups that may have prognostic and clinical relevance.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Oncology
Hirokazu Takami, Akitake Mukasa, Shunsaku Takayanagi, Tsukasa Koike, Reiko Matsuura, Masako Ikemura, Tetsuo Ushiku, Gakushi Yoshikawa, Junji Shibahara, Shota Tanaka, Nobuhito Saito
Summary: Oligoastrocytoma has been removed from the revised fourth edition of the World Health Organization Classification of Tumours of the Central Nervous System, except in cases where it is specified as not otherwise specified (NOS). However, there have been few reports on the histopathological and genetic backgrounds of cases with dual features of astrocytoma/oligodendroglioma. In this study, a case of a 54-year-old man with a glioma containing two distinct parts, astrocytoma and oligodendroglioma, was encountered. The findings suggest that gliomas with two distinct lineages might mix to produce oligoastrocytoma, and genetic alterations may be acquired during chemo-radiotherapy.
BRAIN TUMOR PATHOLOGY
(2023)
Article
Oncology
Grace S. Ahn, Kihwan Hwang, Tae Min Kim, Chul Kee Park, Jong Hee Chang, Tae-Young Jung, Jin Hee Kim, Do-Hyun Nam, Se-Hyuk Kim, Heon Yoo, Yong-Kil Hong, Eun-Young Kim, Dong-Eun Lee, Jungnam Joo, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Seok-Gu Kang, Jeong Hoon Kim, Chae-Yong Kim
Summary: The addition of concurrent and adjuvant temozolomide did not negatively impact health-related quality of life (HRQoL) and was associated with improved progression-free survival (PFS) for patients with anaplastic gliomas.
CANCER RESEARCH AND TREATMENT
(2022)
Review
Clinical Neurology
Sebastian Brandner, Alexandra McAleenan, Hayley E. Jones, Ashleigh Kernohan, Tomos Robinson, Lena Schmidt, Sarah Dawson, Claire Kelly, Emmelyn Spencer Leal, Claire L. Faulkner, Abigail Palmer, Christopher Wragg, Sarah Jefferies, Luke Vale, Julian P. T. Higgins, Kathreena M. Kurian
Summary: Codeletion of chromosomal arms 1p and 19q, together with the mutation in isocitrate dehydrogenase 1 or 2 gene, is the molecular diagnostic criterion for oligodendroglioma. Different techniques, including FISH and PCR-based LOH, showed good sensitivity for detecting 1p/19q codeletions in glioma. NGS and SNP array had high specificity when compared to FISH. MLPA was found to be marginally more cost-effective.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
(2022)
Review
Oncology
Jasmin Jo, David Schiff
Summary: Treatment recommendations for grade 3 gliomas depend on their histopathologic and molecular phenotype. The current treatments involve surgery, radiation therapy, and chemotherapy. The addition of temozolomide after radiation therapy improves outcomes for non-codeleted grade 3 IDH mutant astrocytoma. For codeleted oligodendroglioma, the recommended treatment includes procarbazine, CCNU, and vincristine regimen. Novel agents targeting IDH mutation and its metabolic effects are being investigated to further improve patient outcomes.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Article
Pathology
Aparna Pallavajjala, Lisa Haley, Victoria Stinnett, Emily Adams, Roshni Pallavajjala, Jialing Huang, Laura Morsberger, Melanie Hardy, Patty Long, Christopher D. Gocke, James R. Eshleman, Fausto J. Rodriguez, Ying S. Zou
Summary: Molecular classification of brain neoplasms is crucial for diagnosis, prognosis, and treatment outcomes. This proof-of-concept study demonstrated the feasibility of using targeted next-generation sequencing (NGS) to simultaneously detect 1p/19q co-deletion and somatic mutations, providing a more comprehensive genetic profiling for glioma patients.
Article
Oncology
Antonio Omuro, Alba A. Brandes, Antoine F. Carpentier, Ahmed Idbaih, David A. Reardon, Timothy Cloughesy, Ashley Sumrall, Joachim Baehring, Martin van den Bent, Oliver Bahr, Giuseppe Lombardi, Paul Mulholland, Ghazaleh Tabatabai, Ulrik Lassen, Juan Manuel Sepulveda, Mustafa Khasraw, Elodie Vauleon, Yoshihiro Muragaki, Anna Maria Di Giacomo, Nicholas Butowski, Patrick Roth, Xiaozhong Qian, Alex Z. Fu, Yanfang Liu, Von Potter, Alexandros-Georgios Chalamandaris, Kay Tatsuoka, Michael Lim, Michael Weller
Summary: This study showed that TMZ + RT had better efficacy than NIVO + RT in newly diagnosed GBM patients with unmethylated MGMT promoter. However, no new safety signals were detected with NIVO in this study.
Article
Oncology
Philipp Karschnia, Jacob S. Young, Antonio Dono, Levin Haeni, Tommaso Sciortino, Francesco Bruno, Stephanie T. Juenger, Nico Teske, Ramin A. Morshed, Alexander F. Haddad, Yalan Zhang, Sophia Stoecklein, Michael Weller, Michael A. Vogelbaum, Juergen Beck, Nitin Tandon, Shawn Hervey-Jumper, Annette M. Molinaro, Roberta Ruda, Lorenzo Bello, Oliver Schnell, Yoshua Esquenazi, Maximilian Ruge, Stefan J. Grau, Mitchel S. Berger, Susan M. Chang, Martin van den Bent, Joerg-Christian Tonn
Summary: This study investigated the prognostic value of the extent of resection in glioblastoma, finding that smaller volumes of residual contrast-enhancing tumor were associated with better outcomes. Additionally, removing non-contrast-enhancing tumor beyond the tumor borders resulted in improved survival. These findings have significant implications for stratification in clinical trials.
Article
Oncology
Sebastian R. van der Voort, Fatih Incekara, Maarten M. J. Wijnenga, Georgios Kapsas, Renske Gahrmann, Joost W. Schouten, Rishi Nandoe Tewarie, Geert J. Lycklama, Philip C. De Witt Hamer, Roelant S. Eijgelaar, Pim J. French, Hendrikus J. Dubbink, Arnaud J. P. E. Vincent, Wiro J. Niessen, Martin J. van den Bent, Marion Smits, Stefan Klein
Summary: We developed a method that can non-invasively predict multiple clinically relevant features of glioma, and it performs well and generalizes well in an independent dataset.
Article
Oncology
David Capper, Guido Reifenberger, Pim J. French, Leonille Schweizer, Michael Weller, Mehdi Touat, Simone P. Niclou, Philipp Euskirchen, Christine Haberler, Monika E. Hegi, Sebastian Brandner, Emilie Le Rhun, Roberta Ruda, Marc Sanson, Ghazaleh Tabatabai, Felix Sahm, Patrick Y. Wen, Pieter Wesseling, Matthias Preusser, Martin J. van den Bent
Summary: The mainstay of treatment for adult patients with gliomas, glioneuronal and neuronal tumors consists of combinations of surgery, radiotherapy, and chemotherapy. For many systemic cancers, targeted treatments are a part of the standard of care, however, the predictive significance of most of these targets in central nervous system (CNS) tumors remains less well-studied.
Review
Oncology
Johan M. Kros, Elisabeth Rushing, Aime L. Uwimana, Aurelio Hernandez-Lain, Alex Michotte, Maysa Al-Hussaini, Franck Bielle, Christian Mawrin, Gianluca Marucci, C. Mircea S. Tesileanu, Roger Stupp, Brigitta Baumert, Martin van den Bent, Pim J. French, Thierry Gorlia
Summary: The histologic parameters, especially the mitotic count, provide additional prognostic value in IDH mutant astrocytomas. The mitotic count significantly affects the PFS and marginally the OS. Furthermore, the mitotic count also affects the PFS of tumors with CDKN2A/B homozygous deletion.
Article
Oncology
Youri Hoogstrate, Kaspar Draaisma, Santoesha A. Ghisai, Levi van Hijfte, Nastaran Barin, Iris de Heer, Wouter Coppieters, Thierry P. P. van den Bosch, Anne Bolleboom, Zhenyu Gao, Arnaud J. P. E. Vincent, Latifa Karim, Manon Deckers, Martin J. B. Taphoorn, Melissa Kerkhof, Astrid Weyerbrock, Marc Sanson, Ann Hoeben, Slavka Lukacova, Giuseppe Lombardi, Sieger Leenstra, Monique Hanse, Ruth E. M. Fleischeuer, Colin Watts, Nicos Angelopoulos, Thierry Gorlia, Vassilis Golfinopoulos, Vincent Bours, Martin J. van den Bent, Pierre A. Robe, Pim J. French
Summary: A better understanding of the transcriptional evolution of IDH-wild-type glioblastoma is crucial for optimizing treatment. Through RNA sequencing, this study demonstrates that glioblastomas mainly evolve through microenvironmental reorganization rather than molecular evolution of tumor cells. The changes in tumor composition over time, including alterations in neuron and oligodendrocyte marker genes and an increase in tumor-associated macrophages, are confirmed by single-cell RNA-seq and immunohistochemistry.
Article
Oncology
Caroline Hertler, Joerg Felsberg, Dorothee Gramatzki, Emilie Le Rhun, Jennifer Clarke, Riccardo Soffietti, Wolfgang Wick, Olivier Chinot, Francois Ducray, Patrick Roth, Kerrie McDonald, Peter Hau, Andreas F. Hottinger, Jaap Reijneveld, Oliver Schnell, Christine Marosi, Michael Glantz, Amelie Darlix, Giuseppe Lombardi, Dietmar Krex, Martin Glas, David A. Reardon, Martin van den Bent, Florence Lefranc, Ulrich Herrlinger, Evangelia Razis, Antoine F. Carpentier, Samuel Phillips, Roberta Ruda, Antje Wick, Emeline Tabouret, David Meyronet, Claude-Alain Maurage, Elisabeth Rushing, Robert Rapkins, Elisabeth Bumes, Monika Hegi, Astrid Weyerbrock, Dawit Aregawi, Christian Gonzalez-Gomez, Alessia Pellerino, Martin Klein, Matthias Preusser, Martin Bendszus, Vassilis Golfinopoulos, Andreas von Deimling, Thierry Gorlia, Patrick Y. Wen, Guido Reifenberger, Michael Weller
Summary: This study analyzed patients with glioblastoma who survived at least 5 years and found that only a few patients can survive for longer periods. The characteristics and factors associated with long-term survival remain poorly defined.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Jaap C. Reijneveld, Abigirl Machingura, Corneel Coens, Martin J. B. Taphoorn, Walter Taal, Paul M. Clement, Ahmed Idbaih, Filip Y. F. Vos, Martin Klein, Wolfgang Wick, Paul J. Mulholland, Joanne Lewis, Vassilis Golfinopoulos, Irina Ghislain, Andrew Bottomley, Martin J. van den Bent, EORTC Brain Tumor Grp
Summary: In an international study, the addition of bevacizumab to temozolomide did not significantly improve or negatively affect health-related quality of life (HRQoL) in patients with non1p/19q co-deleted WHO grade 2 or 3 gliomas. The study assessed HRQoL using several scales and found no clinically significant differences between the treatment arms.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Ivan Caramanna, Jaap C. Reijneveld, Peter M. van de Ven, Martin van de Bent, Ahmed Idbaih, Wolfgang Wick, Martin J. B. Taphoorn, Linda Dirven, Andrew Bottomley, Martin Klein
Summary: This study evaluated the cognitive awareness of patients with recurrent high-grade glioma (HGG) and found an association between neurocognitive functioning and complaints. The findings suggest that patients' awareness of their neurocognitive limitations should be considered in clinical decision-making and interpretation of patient-reported outcomes (PROs).
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Clinical Neurology
M. J. van den Bent
Summary: This paper reviews the 30-year development of low-grade gliomas, including changes in diagnostics with the incorporation of 1p/19q and IDH mutations, improved surgical techniques, and improved delivery of radiotherapy and chemotherapy. Recently, the better understanding of altered cellular processes has led to the development of novel drugs that may completely alter the management of patients early in their disease.
REVUE NEUROLOGIQUE
(2023)
Review
Oncology
Pim B. van der Meer, Linda Dirven, Marta Fiocco, Maaike J. Vos, Melissa Kerkhof, Mathilde C. M. Kouwenhoven, Martin J. van den Bent, Martin J. B. Taphoorn, Johan A. F. Koekkoek
Summary: The risk of seizure recurrence is relatively similar between glioma patients with short-term, medium-term, and long-term seizure freedom after completing antitumor treatment.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Oncology
Maximilian Niyazi, Nicolaus Andratschke, Martin Bendszus, Anthony J. Chalmers, Sara C. Erridge, Norbert Galldiks, Frank J. Lagerwaard, Pierina Navarria, Per Munck af Rosenschoeld, Umberto Ricardi, Martin J. van den Bent, Michael Weller, Claus Belka, Giuseppe Minniti
Summary: This guideline aims to update the existing European consensus on delineation of the clinical target volume (CTV) in adult glioblastoma patients. It discusses key issues including pre-treatment steps, target delineation, and technical aspects of treatment. Based on the EORTC recommendation, a single CTV definition using post-operative contrast-enhanced T1 abnormalities is recommended, without the need to cone down. The PTV margin should be based on individual mask system and IGRT procedures, usually no greater than 3 mm.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Oncology
Jaap P. M. Jaspers, Walter Taal, Yvette van Norden, Jaap D. Zindler, Annemarie T. Swaak, Steven J. M. Habraken, Mischa S. Hoogeman, Remi Nout, Martin J. van den Bent, Alejandra Mendez Romero
Summary: This study aimed to characterize and classify new enhancing lesions in patients with IDH mutated grade 2 diffuse glioma treated with photon therapy. The cumulative incidence of pseudoprogression (psPD) increased over time, and the presence of an 1p/19q codeletion was associated with an increased risk of psPD.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Wouter H. T. Teunissen, Anna Lavrova, Martin van den Bent, Anouk van der Hoorn, Esther A. H. Warnert, Marion Smits
Summary: This study investigates the correlation and diagnostic accuracy of quantitative cerebral blood flow and non-quantitative perfusion weighted imaging measurements in brain tumour surveillance using arterial spin labelling MRI. The results show that there is a high correlation between ASL-PWI ratios and ASL-CBF ratios and their diagnostic accuracy is comparable. Therefore, quantification of ASL-CBF can be omitted in these patients and visual assessment provides the same diagnostic accuracy as quantitative measurements.
EUROPEAN RADIOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Wouter H. T. Teunissen, Anna Lavrova, Martin van den Bent, Anouk van der Hoorn, Esther A. H. Warnert, Marion Smits
Summary: ASL-PWI has higher diagnostic accuracy than ASL-CBF, indicating that quantification of ASL-CBF can be omitted for brain tumour surveillance.
EUROPEAN RADIOLOGY
(2023)